RT Journal Article
SR Electronic
T1 Correlating hippocampal and amygdala volumes with neuropathological burden in neurodegenerative diseases using 7T postmortem MRI
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.15.24307354
DO 10.1101/2024.05.15.24307354
A1 Liou, Jr-Jiun
A1 Li, Jinghang
A1 Berardinelli, Jacob
A1 Jin, Hecheng
A1 Santini, Tales
A1 Noh, Jaehoon
A1 Farhat, Nadim
A1 Wu, Minjie
A1 Aizenstein, Howard
A1 Mettenburg, Joseph M
A1 Yong, William
A1 Head, Elizabeth
A1 Ikonomovic, Milos
A1 Ibrahim, Tamer
A1 Kofler, Julia
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/05/15/2024.05.15.24307354.abstract
AB Numerous research groups worldwide have focused on postmortem imaging to bridge the resolution gap between clinical neuroimaging and neuropathology data. We developed a standardized protocol for brain embedding, imaging, and processing, facilitating alignment between antemortem MRI, postmortem MRI, and pathology to observe brain atrophy and structural damage progression over time. Using 7T postmortem ex vivo MRI, we explore the potential correlation of amygdala and hippocampal atrophy with neuropathological burden in both Down syndrome (DS) and Alzheimer’s disease (AD) cohorts. Using 7T postmortem ex vivo MRI scans from 66 cases (12 DS and 54 AD) alongside a subset of antemortem scans (n=17), we correlated manually segmented hippocampal and amygdala volumes, adjusted for age, sex, and ApoE4 status, with pathological indicators such as Thal phase, Braak stage, limbic-predominant age-related TDP-43 encephalopathy (LATE) stage, hippocampal sclerosis (HS), and Lewy body (LB) stage. A significant correlation was observed between postmortem and antemortem volumes for the hippocampus, but a similar trend observed for the amygdala did not reach statistical significance. DS individuals exhibited notably smaller hippocampal and amygdala volumes compared to AD subjects. In DS, lower hippocampal and amygdala volumes correlated with more severe Braak stage, without significant associations with Thal phase. LATE and HS pathologies were uncommon in DS cases but trended toward smaller hippocampal volumes. In AD, lower hippocampal volume associated with dementia duration, advanced Thal phase, Braak stage, LATE stage, and HS presence, whereas reduced amygdala volume correlated mainly with severe LATE stage and HS, but not with Thal or Braak stages. No significant LB correlation was detected in either DS or AD cohorts. Hippocampal volume in AD appears influenced by both AD and LATE pathologies, while amygdala volume seems primarily influenced by LATE. In DS, smaller hippocampal volume, relative to AD, appears primarily influenced by tau pathology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Institutes of Health R01 AG063525, R01 MH111265, P30 AG066468, R01 AG069912, U19 AG068054, P30 AG066519 and the Alzheimer Biomarkers Consortium Down Syndrome and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (U01 AG051406 and U01 AG051412), as well as the Bioengineering in Psychiatry Training Program (T32 MH119168).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Committee for Oversight and Research and Clinical Training Involving Decedents of the University of Pittsburgh gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript 3Dthree-dimensionalADAlzheimer’s diseaseApoE4apolipoprotein E allele 4DSDown syndromeDSMSEDown syndrome mental status examinationGREGRadient EchoHShippocampal sclerosisLATElimbic-predominant age-relatedTDP-43encephalopathyLBLewy bodyMMSEmini mental state examinationMP2RAGEMagnetization Prepared – RApid Gradient EchoMRImagnetic resonance imagingNFTneurofibrillary tangleSPACESampling Perfection with Application optimized Contrast using different flip angle EvolutionTDP-43TAR DNA-binding protein 43PMIpostmortem interval